The representative suggested that the traditional Chinese medicine industry should be promoted to the value chain

Xiao Wei, deputy to the National People's Congress and chairman of Jiangsu Kangyuan Pharmaceutical Co., Ltd., said in a speech at the plenary session of the delegation that we should take scientific and technological innovation as the driving force to promote the leap of traditional Chinese medicine industry to the value chain The representative of Xiao Wei said that Premier Li Keqiang was encouraged by his discussion on encouraging innovation in the government work report The report puts forward that "innovation should be placed at the core of the overall national development, science and technology should be closely integrated with economic and social development, and China's industry should be promoted to the global value chain", so that he has more confidence in the innovation and development of traditional Chinese medicine The representative of Xiao Wei said that the state should speed up the reform of science and technology system, strengthen the dominant position of enterprises in technological innovation, make innovative varieties enjoy corresponding market access, preferential policies and due "national treatment" after listing, and encourage enterprises to actively increase investment in science and technology It is suggested that the national innovation fund should be more invested in the field of basic research, while the research and development of innovative varieties should be based on the enterprises, which should give preferential tax and policy support to the innovative products after being approved for listing, get rid of the threshold restrictions of market access as soon as possible, open up green channels in bidding and price, so that the innovative Chinese medicine can enter the catalogue of medical insurance and basic drugs in time, and serve the people's livelihood faster and better 。 On the issue of internationalization of traditional Chinese medicine, representative Xiao Wei suggested that the State Food and drug administration, the State Administration of traditional Chinese medicine and the Ministry of science and technology should take the lead to establish a communication platform at the level of Chinese and American governments and improve the interaction and communication mechanism of international drug registration agencies by referring to the mode of communication between the State Pharmacopoeia Committee and the United States Pharmacopoeia Committee The representative of Xiao Wei also said that we should objectively and scientifically understand the adverse reactions of traditional Chinese medicine and proprietary Chinese medicine, especially traditional Chinese medicine injection, based on the in-depth basic research and market re evaluation research of traditional Chinese medicine We should not completely deny the traditional Chinese medicine due to the problems of individual drugs, and then take unreasonable restrictions on the access of relevant catalogues It is suggested that the state, while encouraging the research and development of original new drugs, should actively promote the re evaluation of large varieties of traditional Chinese medicine, especially injection of traditional Chinese medicine.